Lucia Moreno
Family · Kansas City, KSNPI 1720435878
Payments from drug & device makers
Across 233 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$676
- Lilly USA, LLC$504
- Novartis$256
- Merck$225
- Lundbeck LLC$205
- Novo Nordisk$200
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,880100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,880 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 53 | $66,530 |
| RexultiBrexpiprazole | 26 | $58,057 |
| MounjaroTirzepatide | 56 | $56,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $27,512 |
| JanuviaSitagliptin Phosphate | 18 | $24,310 |
| FarxigaDapagliflozin Propanediol | 24 | $19,520 |
| GemtesaVibegron | 12 | $14,313 |
| XareltoRivaroxaban | 15 | $11,642 |
| EliquisApixaban | 16 | $11,461 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 291 | $10,581 |
| BelsomraSuvorexant | 14 | $6,133 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $6,007 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,129 |
| OxycontinOxycodone Hcl | 11 | $4,966 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $3,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $12 | $66,53053 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $174 | $58,05726 claims |
| Lilly USA, LLCMounjaro | $504 | $56,03656 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $117 | $32,64251 claims |
| MerckJanuvia, Belsomra | $225 | $30,44232 claims |
| AstraZenecaFarxiga | $177 | $19,52024 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $124 | $14,31312 claims |
| Johnson & JohnsonXarelto | $26 | $11,64215 claims |
| PfizerEliquis | $79 | $11,46116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.
Other family in Kansas City
- Zohra HussainiKansas City$329K
- Adam CaseKansas City$34K
- Kristina DelaneyKansas City$27K
- Amanda WilliamsKansas City$20K
- Mindy EldridgeKansas City$12K
- Liza RodriguezKansas City$11K
- Jhunne GalimbaKansas City$6K
- Graceann SandriKansas City$6K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.